SERUM NT-PROBNP AND CRP AS A PROGNOSTIC MARKER IN ACUTE CORONARY SYNDROME IN A TERTIARY CARE HOSPITAL

Abstract

Background: Coronary artery disease (CAD) continues to be a leading cause of morbidity and mortality worldwide. Although NT-proBNP is the preferred biomarker for heart failure (HF), several studies have suggested that NT-proBNP is also a risk marker for major adverse cardiovascular events (MACE) in the general population and in CAD patients. Numerous studies have shown that CRP has independent prognostic relevance for the risk of cardiovascular events in patients with CAD as well as in the apparently healthy population. This study evaluates the prognostic value of CRP and NT-ProBNP in predicting cardiovascular outcomes in patients presenting with acute coronary syndromes. Methods: This single-centered hospital-based observational study was conducted at the Department of General Medicine and Dept of Cardiology, SMCH from 1st January 2022 to 31st June 2022 for a period of 6 months. We evaluated the prognostic value of NT-proBNP and CRP for adverse outcomes in patients with acute coronary syndromes (ACS). 10 Results: 0 patients were included in the study, out of whom 42(42%) patients were having STEMI (28 male and & 14 female), 48(48%) patients had NSTEMI (36 male, 12 female), and 10(10%) patients had Unstable angina (6 male and 4 female). The elevated levels of NT-proBNP and CRP levels were correlated and found to provide important information for risk stratification across the entire spectrum of ACS. NT proBNP and CRP are more commonly elevated in S Conclusion: TEMI than NSTEMI or Unstable Angina. NT proBNP and CRP are reliable prognostic biomarkers in ACS